 Patients with antineutrophil cytoplasmic antibody ANCA associated vasculitis AAV have inflammation in the small blood vessels leading to involvement in different body areas, e.g., the kidneys, lungs and skin. Untreated, the risk of death is over 80; with current treatment, patients often suffer from ongoing disease activity, damage or treatment side effects which have a negative impact on quality of life. Because patients with AAV can have a wide range of disease features, the investigators hypothesise that general patient reported outcome PROs measurements, may not be specific enough to describe the full impact on quality of life. 